TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What are the treatment options for patients with MCL who relapse after BTKi therapy?

By Sabina Ray

Share:

Featured:

Chan CheahChan Cheah

Aug 9, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in MCL.


During the European Hematology Association (EHA) 2023 Congress, the Lymphoma Hub spoke to Chan Cheah, Sir Charles Gairdner Hospital, Perth, AU. We asked, What are the treatment options for patients with MCL who relapse after BTKi therapy?

What are the treatment options for patients with MCL who relapse after BTKi therapy?

Outcomes for patients with mantle cell lymphoma (MCL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) can be poor, with a median overall survival of 6–12 months. Here, Cheah discusses the benefits and drawbacks of different agents considered for patients with BTKi relapsed/refractory MCL, including chimeric antigen receptor T-cell therapies, non-covalent BTKis, and bi-specific antibodies. Not all these therapies are globally available; therefore, he discusses the importance of enrolling patients with MCL for clinical trials to help develop new treatments.